We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms.
- Authors
Laskaratos, Faidon-Marios; Armeni, Eleni; Shah, Heer; Megapanou, Maria; Papantoniou, Dimitrios; Hayes, Aimee R; Navalkissoor, Shaunak; Gnanasegaran, Gopinath; von Stempel, Conrad; Phillips, Edward; Furnace, Myles; Kamieniarz, Lukasz; Kousteni, Margarita; Luong, Tu Vinh; Watkins, Jennifer; Mandair, Dalvinder; Caplin, Martyn; Toumpanakis, Christos
- Abstract
Purpose: The antiproliferative properties of lanreotide autogel (LAN) in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) were demonstrated in the CLARINET study. However, there is limited literature regarding factors that affect progression-free survival (PFS) in patients with GEP NENs treated with LAN. Methods: We identified a total of 191 treatment-naive patients with advanced GEP NENs and positive SSTR uptake on imaging (Octreoscan or 68Gallium DOTATATE Positron Emission Tomography [68GaPET]) who received first-line LAN monotherapy, albeit at various starting doses (60, 90 or 120 mg/month). A group of 102 patients who initiated treatment at the standard dose of 120 mg/month were included in the study and further evaluated by univariate and multivariate analyses to identify predictors of PFS. Results: The location of tumour primary was in the small bowel in 63 (62%), pancreas in 31 (30%) and colon/rectum in 8 patients (8%). The tumours were well-differentiated, and the majority were grade 1 (52%), or 2 (38%). About 60% of cases had progressive disease at the time of treatment initiation. Most patients with available pretreatment nuclear medicine imaging (Octreoscan or 68Ga PET) had a Krenning score of 3 (44%) or 4 (50%). The median PFS for the entire cohort was 19 months (95% CI 12, 26 months). The univariate analysis demonstrated that grade 2 tumours, progressive disease at baseline and metastatic liver disease were associated with a significantly shorter PFS, while other evaluated variables did not affect PFS at a statistically significant level. However, at multivariate analysis only the tumour grade remained statistically significant. Conclusions: The current study showed that, of many evaluated variables, only the tumour grade was predictive of PFS duration and this should be considered during patient selection for treatment.
- Publication
Endocrine (1355008X), 2020, Vol 67, Issue 1, p233
- ISSN
1355-008X
- Publication type
Article
- DOI
10.1007/s12020-019-02086-6